Literature DB >> 25804434

Solid state compatibility study and characterization of a novel degradation product of tacrolimus in formulation.

Tanja Rozman Peterka1, Rok Grahek2, Jure Hren2, Andrej Bastarda2, Jure Bergles2, Uroš Urleb2.   

Abstract

Tacrolimus is macrolide drug that is widely used as a potent immunosuppressant. In the present work compatibility testing was conducted on physical mixtures of tacrolimus with excipients and on compatibility mixtures prepared by the simulation of manufacturing process used for the final drug product preparation. Increase in one major degradation product was detected in the presence of magnesium stearate based upon UHPLC analysis. The degradation product was isolated by preparative HPLC and its structure was elucidated by NMR and MS studies. Mechanism of the formation of this degradation product is proposed based on complementary degradation studies in a solution and structural elucidation data. The structure was proven to be alpha-hydroxy acid which is formed from the parent tacrolimus molecule through a benzilic acid type rearrangement reaction in the presence of divalent metallic cations. Degradation is facilitated at higher pH values.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Characterization; Compatibility study; Degradation product; Tacrolimus

Mesh:

Substances:

Year:  2015        PMID: 25804434     DOI: 10.1016/j.jpba.2015.02.047

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Pomegranate seed oil protects against tacrolimus-induced toxicity in the heart and kidney by modulation of oxidative stress in rats.

Authors:  Azar Hosseini; Arezoo Rajabian; Fatemeh Forouzanfar; Mahdi Farzadnia; Mohammad Taher Boroushaki
Journal:  Avicenna J Phytomed       Date:  2022 Jul-Aug

2.  Self-Assembling Tacrolimus Nanomicelles for Retinal Drug Delivery.

Authors:  Vrinda Gote; Abhirup Mandal; Meshal Alshamrani; Dhananjay Pal
Journal:  Pharmaceutics       Date:  2020-11-10       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.